Shots:
- Manifold has entered into a strategic research collaboration & licensing deal with Roche to develop multiple next-gen blood-brain barrier (BBB) shuttles for neurological & neurodegenerative diseases, leveraging Manifold’s shuttle portfolio & mDesign AI-driven in vivo discovery platform
- As per the deal, Manifold will lead research & discovery of BBB shuttles for Roche’s therapeutic payloads, while Roche will handle preclinical to commercial activities. Manifold will receive $55M upfront & over $2B in research, discovery, preclinical, clinical & sales milestones, along with tiered royalties
- Additionally, Manifold reserves the right to co-fund one program for higher royalties & may utilize its BBB shuttles with therapeutic payloads beyond Roche’s licensed targets
Ref: Manifold Bio | Image: Manifold Bio & Roche | Press Release
Related News:- 4D Molecular Therapeutics Collaborates with Otsuka Pharmaceutical to Develop and Commercialize 4D-150 in the APAC Region
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
